Seeking Alpha

Medivation (MDVN) resumed trading just before the close, up 7.6% on the back of the FDA...

Medivation (MDVN) resumed trading just before the close, up 7.6% on the back of the FDA announcement of an early approval for it and Astellas Pharma's enzalutamide capsules for the treatment of patients with metastatic castration-resistant prostate cancer.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)